Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will likely be announcing its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $7.23 million for the quarter.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.81. The company had revenue of $84.93 million during the quarter, compared to analysts’ expectations of $13.57 million. Monte Rosa Therapeutics had a net margin of 3.86% and a return on equity of 2.65%. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE opened at $4.38 on Thursday. The firm’s 50 day simple moving average is $4.99 and its 200-day simple moving average is $5.18. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $12.40. The firm has a market cap of $269.41 million, a PE ratio of 54.76 and a beta of 1.42.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GLUE. Acadian Asset Management LLC purchased a new position in Monte Rosa Therapeutics during the first quarter valued at approximately $76,000. Goldman Sachs Group Inc. boosted its position in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Monte Rosa Therapeutics during the 1st quarter valued at $1,065,000. 79.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Monte Rosa Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.